Compare MXE & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MXE | COCH |
|---|---|---|
| Founded | 1990 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Blank Checks |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.7M | 51.3M |
| IPO Year | 1994 | 2021 |
| Metric | MXE | COCH |
|---|---|---|
| Price | $12.98 | $7.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $21.67 |
| AVG Volume (30 Days) | 2.7K | ★ 20.3K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ 17.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $241,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $11.57 | $4.72 |
| 52 Week High | $14.30 | $47.70 |
| Indicator | MXE | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 55.77 | 18.22 |
| Support Level | $12.79 | $4.72 |
| Resistance Level | $13.55 | $36.51 |
| Average True Range (ATR) | 0.27 | 0.67 |
| MACD | 0.06 | 0.86 |
| Stochastic Oscillator | 70.59 | 88.32 |
Mexico Equity and Income Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek high total return through capital appreciation and current income. It invests in equity securities, convertible securities and debt securities and may also invest in other securities such as capital development certificates, real estate investment trusts, mutual funds, exchange traded funds, preferred stocks, rights and warrants.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.